2015
DOI: 10.1016/j.clinbiochem.2015.03.024
|View full text |Cite
|
Sign up to set email alerts
|

Recombinant, truncated B. circulans keratanase-II: Description and characterisation of a novel enzyme for use in measuring urinary keratan sulphate levels via LC–MS/MS in Morquio A syndrome

Abstract: This novel, recombinant keratanase-II meets all performance requirements and can be produced in a rapid and reproducible manner. We speculate that other related bacterial enzymes of biomedical or industrial interest may be amenable to similar engineered enhancements.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 25 publications
0
4
0
Order By: Relevance
“…and Chondroitinase ABC ( Proteus vulgaris ) were from Amsbio (Cambridge, MA). A recombinant truncated form of Keratanase II ( Bacillus circulans ) was produced in Escherichia coli using an expression plasmid kindly provided by Dr. Andrew Muscroft-Taylor, GlycoSyn, New Zealand and expressed and purified essentially as described ( Steward et al 2015 ). Recombinant Vibrio cholerae sialidase was kindly provided by Dr Garry Taylor, University of St. Andrews, and purified produced in E. coli from an expression plasmid as described ( Moustafa et al 2004 ; Mountney et al 2010 ).…”
Section: Methodsmentioning
confidence: 99%
“…and Chondroitinase ABC ( Proteus vulgaris ) were from Amsbio (Cambridge, MA). A recombinant truncated form of Keratanase II ( Bacillus circulans ) was produced in Escherichia coli using an expression plasmid kindly provided by Dr. Andrew Muscroft-Taylor, GlycoSyn, New Zealand and expressed and purified essentially as described ( Steward et al 2015 ). Recombinant Vibrio cholerae sialidase was kindly provided by Dr Garry Taylor, University of St. Andrews, and purified produced in E. coli from an expression plasmid as described ( Moustafa et al 2004 ; Mountney et al 2010 ).…”
Section: Methodsmentioning
confidence: 99%
“…Before electrophoresis, as indicated, some nasal lavage samples were treated with hydrolytic enzymes to identify functional binding determinants. To equal aliquots we added buffer alone (control), 7 mU/mL of keratanase I (Pseudomonas spp [Amsbio, Abingdon, United Kingdom]), 7 mU/mL of keratanase II (Bacillus circulans expressed in Escherichia coli) prepared as described, 13 0.25 U/mL of chondroitinase ABC, 0.25 U/mL of heparinase (H3917, MilliporeSigma), or 76 mU/mL of sialidase (V cholerae expressed in E coli as described). 12 Samples were incubated at 378C for 20 hours (except for sialidase, which was incubated for 1.5 hours) before electrophoresis.…”
Section: Molecular Analyses Of Human Fluids and Tissuesmentioning
confidence: 99%
“…9 Similarly, to degrade keratan sulfate glycosaminoglycans, sections were incubated with 50 µg/ml (dissolved in 30 mM sodium acetate, pH 5.2) of recombinant keratanase II (from Bacillus circulans) prepared as described. 10 To cleave internal β1,4galactosidic linkages in non-sulfated or GlcNAc-6-Osulfated oligo-or poly-N-acetyllactosamine, sections were incubated with 50 µg/ml (dissolved in 30 mM sodium acetate, pH 5.2) of endo-β-galactosidase (from Citrobacter freundii) purified as described. 11,12 As positive controls for enzymatic digestion, we performed immunohistochemistry with 5D4 antibody using porcine corneal tissues rich in N-glycosidically linked keratan sulfate glycosaminoglycans (Supplemental Figs.…”
Section: Pretreatment Of Tissue Sectionsmentioning
confidence: 99%